# Obefazimod PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/obefazimod

> The next catalyst for obefazimod, sponsored by Abivax S.A. (ABVX), is its primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | obefazimod |
| Codes | ABX464 |
| Sponsor | Abivax S.A. (ABVX) https://sec-api.dev/companies/abvx/catalysts |
| Indications | chronic inflammatory diseases, today, [crohns disease](https://sec-api.dev/indications/crohn-s-disease), [crohn's disease](https://sec-api.dev/indications/crohn-s-disease), [Ulcerative Colitis](https://sec-api.dev/indications/ulcerative-colitis), [Moderately to Severely Active Crohn Disease](https://sec-api.dev/indications/moderately-to-severely-active-crohn-disease) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Oct 2024: trial start

- Status: completed. Date confidence: month. Stage: 2. Indication: Crohn's disease.
- First seen 2025-03-24, last confirmed 2025-07-24.
- SEC prospectus (424B) (accession 0001193125-25-164456): "We have also initiated a Phase 2b clinical trial of obefazimod in patients with Crohns disease (CD), with our first patient enrolled in October 2024, and we are evaluating other potential inflammatory indications." https://www.sec.gov/Archives/edgar/data/1956827/000119312525164456/d945355d424b5.htm
- SEC Form 10-K (accession 0001956827-25-000010): "We have also initiated a Phase 2b clinical trial of obefazimod in patients with Crohn's disease ("CD"), with our first patient enrolled in October 2024, and we are evaluating other potential inflammatory indications." https://www.sec.gov/Archives/edgar/data/1956827/000195682725000010/abvx-20241231.htm

### June 24, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05507203 (ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." https://clinicaltrials.gov/study/NCT05507203

### June 24, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05507216 (ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." https://clinicaltrials.gov/study/NCT05507216

### Q3 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-01-10, last confirmed 2025-04-29.
- Press release filed with the SEC (EX-99) (accession 0001956827-25-000016): "We remain fully committed to advancing this pivotal program: we expect to report top-line induction results in Q3 2025, followed by comprehensive long-term maintenance data in Q2 2026." https://www.sec.gov/Archives/edgar/data/1956827/000195682725000016/exhibit991-abtectfullenrol.htm
- Press release filed with the SEC (EX-99) (accession 0001956827-25-000016): "•Top-line results from the 8-week induction trials anticipated in Q3 2025, with 44-week maintenance data on track for Q2 2026 and, if successful, NDA submission planned for H2 2026." https://www.sec.gov/Archives/edgar/data/1956827/000195682725000016/exhibit991-abtectfullenrol.htm
- Press release filed with the SEC (EX-99) (accession 0001956827-25-000016): "•Top-Line Results: Induction trials topline data expected in Q3 2025, with 44-week maintenance topline data expected in Q2 2026." https://www.sec.gov/Archives/edgar/data/1956827/000195682725000016/exhibit991-abtectfullenrol.htm
- Press release filed with the SEC (EX-99) (accession 0001956827-25-000004): "Our cash position secures a projected financial runway into Q4 2025, supporting the full enrollment of ABTECT in Q2 2025 and the anticipated top-line results from the 8-week induction trials in Q3 2025, a major inflection point for Abivax."" https://www.sec.gov/Archives/edgar/data/1956827/000195682725000004/a6-kpressreleaseq42024fina.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-004163): "Mr. de Garidel went on to say, In order to ensure a balanced representation of bio-na&iuml;ve and bio-experienced participants amid heightened competition in UC trial recruitment, we now anticipate completing enrollment in Q2 2025 and delivering top-line results for the 8-week induction trial in Q3 2025." https://www.sec.gov/Archives/edgar/data/1956827/000119312525004163/d905529dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-004163): "Top-Line Results: Induction trial results expected in Q3 2025, with 44-week maintenance data to follow in Q2 2026." https://www.sec.gov/Archives/edgar/data/1956827/000119312525004163/d905529dex991.htm

### July 22, 2025: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2024-12-23, last confirmed 2025-07-22.
- Press release filed with the SEC (EX-99) (accession 0001193125-25-162671): "Paris: FR0012333284  ABVX / Nasdaq: ABVX) (Abivax or the Company), a clinical-stage biotechnology company focused on developing therapeutics that harness the bodys natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced positive topline results from its Phase 3 ABTECT-1 (Study 105) and ABTECT-2 (Study 106) 8-week induction trials evaluating its oral, first-in-class miR-124 enhancer, obefazimod (ABX464), in adult patients with moderately to severely active ulcerative colitis (UC)." https://www.sec.gov/Archives/edgar/data/1956827/000119312525162671/d56921dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001956827-25-000004): "•Full enrollment in Phase 3 ABTECT trial evaluating obefazimod for moderately to severely active ulcerative colitis ("UC") expected in Q2 2025 with top-line results from the 8-week induction trials expected in Q3 2025" https://www.sec.gov/Archives/edgar/data/1956827/000195682725000004/a6-kpressreleaseq42024fina.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-089339): "Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025" https://www.sec.gov/Archives/edgar/data/1956827/000119312525089339/d919877dex992.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-24-284298): "I expect Truffle Capital to continue to be a great supporter of Abivax as a major shareholder through the next several inflection points, including the expected Phase 3 ABTECT data readout in 2025." https://www.sec.gov/Archives/edgar/data/1956827/000119312524284298/d891803dex991.htm

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-03-24, last confirmed 2025-03-24.
- SEC Form 10-K (accession 0001956827-25-000010): "Under these assumptions and based on the Group's current clinical and operational plans, the Group would have sufficient funds to finance its operations in the fourth quarter of 2025, i.e. through the announcement of its top-line data from the Phase 3 ABTECT-1 and ABTECT-2 induction trials for" https://www.sec.gov/Archives/edgar/data/1956827/000195682725000010/abvx-20241231.htm

### Q1 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-01-10, last confirmed 2026-03-23.
- Press release filed with the SEC (EX-99) (accession 0001956827-26-000010): "These forward-looking statements include statements concerning the potential therapeutic benefit of obefazimod, the expected timing for completion of the Phase 3 ABTECT-UC maintenance trial and Phase 2b ENHANCE-CD induction trial of obefazimod and the availability and timing of results therefrom, the timing of regulatory filings including an NDA submission for obefazimod in UC, Abivax's expectations for regulatory approval and commercialization of obefazimod for UC, Abivax's cash runway, the timing for reporting Abivax's Q1 2026 financial results, Abivax's expectations of announcing of a new independent director, and other statements that are not historical fact." https://www.sec.gov/Archives/edgar/data/1956827/000195682726000010/a6-kpressreleasefy2025fina.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-004163): "These forward-looking statements include statements concerning the Companys expectations for 2025 and 2026, including anticipated timing for top-line data readout of its ABTECT clinical trials and NDA submission, potential therapeutic benefit of obefazimod, and the Companys expected cash runway." https://www.sec.gov/Archives/edgar/data/1956827/000119312525004163/d905529dex991.htm

### April 28, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05535946 (ABTECT - Maintenance): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-04-28 (ACTUAL); Lead Sponsor Abivax S.A.." https://clinicaltrials.gov/study/NCT05535946

### June 1, 2026: topline data readout

- Status: completed, positive. Date confidence: exact. Stage: 3.
- First seen 2026-03-23, last confirmed 2026-06-02.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-252360): "Paris: FR0012333284 - ABVX / Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced positive topline results from the Phase 3 ABTECT maintenance trial evaluating obefazimod, its investigational oral, first-in-class miR-124 enhancer, in adults with moderately to severely active ulcerative colitis ("UC")." https://www.sec.gov/Archives/edgar/data/1956827/000119312526252360/d98688dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001956827-26-000010): "•The Company's pivotal Phase 3 ABTECT maintenance trial evaluating obefazimod for moderately to severely active ulcerative colitis remains on track to report topline results in late Q2 2026" https://www.sec.gov/Archives/edgar/data/1956827/000195682726000010/a6-kpressreleasefy2025fina.htm

### June 29, 2026: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-07-22, last confirmed 2026-07-02.
- SEC prospectus (424B) (accession 0001193125-26-294491): "On June 29, 2026, we announced positive topline results from Part 2 of our Phase 3 ABTECT 44-week maintenance trial evaluating obefazimod, our potential first-in-class oral miR-124 enhancer, in moderate to severely active UC." https://www.sec.gov/Archives/edgar/data/1956827/000119312526294491/d111359d424b5.htm
- SEC prospectus (424B) (accession 0001193125-26-290817): "On June 29, 2026, we announced positive topline results from Part 2 of our Phase 3 ABTECT 44-week maintenance trial evaluating obefazimod, our potential first-in-class oral miR-124 enhancer, in moderate to severely active UC." https://www.sec.gov/Archives/edgar/data/1956827/000119312526290817/d111359d424b5.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-162671): "The ABTECT Maintenance Trial (ABX464-107) is ongoing with top-line results expected to report out in Q2 2026." https://www.sec.gov/Archives/edgar/data/1956827/000119312525162671/d56921dex991.htm
- SEC prospectus (424B) (accession 0001193125-25-164456): "The ABTECT Maintenance Trial (ABX464-107) is ongoing with top-line results expected to report out in the second quarter of 2026." https://www.sec.gov/Archives/edgar/data/1956827/000119312525164456/d945355d424b5.htm
- Press release filed with the SEC (EX-99) (accession 0001956827-26-000010): "We are pleased with the recent DSMB safety update from our ABTECT maintenance trial and remain on track to report topline results from our ABTECT-UC maintenance trial in late Q2 2026." https://www.sec.gov/Archives/edgar/data/1956827/000195682726000010/a6-kpressreleasefy2025fina.htm
- Press release filed with the SEC (EX-99) (accession 0001956827-26-000010): "This positive update supports the continued advancement of the program as the Company remains on track to report topline results from its ABTECT-UC maintenance trials in late Q2 2026." https://www.sec.gov/Archives/edgar/data/1956827/000195682726000010/a6-kpressreleasefy2025fina.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-162671): "Topline maintenance results are expected in Q2 2026, which are intended to support regulatory filings globally." https://www.sec.gov/Archives/edgar/data/1956827/000119312525162671/d56921dex991.htm

### September 10, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05507203 (ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." https://clinicaltrials.gov/study/NCT05507203?tab=results

### September 10, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05507216 (ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-06-24 (ACTUAL); Lead Sponsor Abivax S.A.; Results First Posted 2026-09-10." https://clinicaltrials.gov/study/NCT05507216?tab=results

### Q4 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Moderately to Severely Active Crohn Disease.
- First seen 2026-03-23, last confirmed 2026-11-16T22:20:01.192Z.
- SEC Form 10-K (accession 0001956827-26-000012): "Based on the positive clinical data generated in our UC trials, preclinical studies in dextran sulfate sodium ("DSS") mouse model which provide support for pursuing further development in CD, and underlying biological and mechanistic rationale, we also initiated a Phase 2b clinical trial in patients with CD in the fourth quarter of 2024, with a planned top-line induction data read-out in the fourth quarter of 2026." https://www.sec.gov/Archives/edgar/data/1956827/000195682726000012/abvx-20251231.htm
- ClinicalTrials.gov: "NCT06456593 (Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Abivax S.A.." https://clinicaltrials.gov/study/NCT06456593

### Q4 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-04-29, last confirmed 2026-09-21.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-288752): "Fourth Quarter 2026 - Planned NDA submission for obefazimod in UC" https://www.sec.gov/Archives/edgar/data/1956827/000119312526288752/d110874dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001956827-26-000027): "•End of 2026 - Planned NDA submission for obefazimod in UC" https://www.sec.gov/Archives/edgar/data/1956827/000195682726000027/a6-kpressreleaseq22026fina.htm
- Press release filed with the SEC (EX-99) (accession 0001956827-25-000016): "Should these data confirm obefazimod's safety and efficacy, we plan to submit a New Drug Application to the FDA in the second half of 2026, bringing us ever closer to delivering a desperately needed new therapeutic option."" https://www.sec.gov/Archives/edgar/data/1956827/000195682725000016/exhibit991-abtectfullenrol.htm
- Press release filed with the SEC (EX-99) (accession 0001956827-26-000022): "These forward-looking statements include statements concerning the potential therapeutic benefit of obefazimod, the expected timing for completion of the Phase 3 ABTECT-UC maintenance trial and Phase 2b ENHANCE-CD induction trial of obefazimod and the availability and timing of results therefrom, the timing of regulatory filings including an NDA submission for obefazimod in UC, Abivax's expectations for regulatory approval and commercialization of obefazimod for UC, Abivax's cash runway, the timing for reporting Abivax's half year 2026 financial results, and other statements that are not historical fact." https://www.sec.gov/Archives/edgar/data/1956827/000195682726000022/a6-kpressreleaseq12026fina.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-252360): "Abivax intends to submit an NDA to the FDA in late fourth quarter 2026." https://www.sec.gov/Archives/edgar/data/1956827/000119312526252360/d98688dex991.htm
- Press release filed with the SEC (EX-99) (accession 0001956827-25-000016): "•Top-line results from the 8-week induction trials anticipated in Q3 2025, with 44-week maintenance data on track for Q2 2026 and, if successful, NDA submission planned for H2 2026." https://www.sec.gov/Archives/edgar/data/1956827/000195682725000016/exhibit991-abtectfullenrol.htm

### December 2026: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Moderately to Severely Active Crohn Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06456593 (Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Abivax S.A.." https://clinicaltrials.gov/study/NCT06456593

### 2027: topline data readout

- Status: scheduled. Date confidence: year. Stage: 2.
- First seen 2026-06-02, last confirmed 2026-06-02.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-252360): "Topline results of Phase 2b induction trial for Crohn's disease expected mid-year 2027" https://www.sec.gov/Archives/edgar/data/1956827/000119312526252360/d98688dex991.htm

## Same indication

- [ABX464](https://sec-api.dev/pdufa/abx464) (ABVX)
- [AMJEVITA® (adalimumab)](https://sec-api.dev/pdufa/adalimumab) (ABBV)
- [Brivekimig](https://sec-api.dev/pdufa/brivekimig) (SNY)
- [Duvakitug](https://sec-api.dev/pdufa/duvakitug) (SNY)
- [Eltrekibart](https://sec-api.dev/pdufa/eltrekibart) (LLY)
- [Emvistegrast](https://sec-api.dev/pdufa/emvistegrast) (GILD)
- [Etrasimod](https://sec-api.dev/pdufa/etrasimod) (PFE)
- [Iv tulisokibart](https://sec-api.dev/pdufa/iv-tulisokibart) (MRK)
- [Mirikizumab](https://sec-api.dev/pdufa/mirikizumab) (LLY)
- [Mirikizumab iv](https://sec-api.dev/pdufa/mirikizumab-iv) (LLY)
- [Nx-13 250mg](https://sec-api.dev/pdufa/nx-13) (ABBV)
- [Skyrizi® (risankizumab)](https://sec-api.dev/pdufa/risankizumab) (ABBV)
- [SL-325](https://sec-api.dev/pdufa/sl-325) (STTK)
- [SPY001](https://sec-api.dev/pdufa/spy001) (SYRE)
- [Tilpisertib fosmecarbil](https://sec-api.dev/pdufa/tilpisertib-fosmecarbil) (GILD)
- [Zepbound (tirzepatide)](https://sec-api.dev/pdufa/tirzepatide) (LLY)
- [Xeljanz (tofacitinib citrate)](https://sec-api.dev/pdufa/tofacitinib) (PFE)
- [Entyvio® (vedolizumab)](https://sec-api.dev/pdufa/vedolizumab) (TAK)
- [Vedolizumab iv](https://sec-api.dev/pdufa/vedolizumab-iv) (TAK)
- [Vedolizumab sc](https://sec-api.dev/pdufa/vedolizumab-sc) (TAK)
- [Zasocitinib](https://sec-api.dev/pdufa/zasocitinib) (TAK)
- [Zotemtegrast](https://sec-api.dev/pdufa/zotemtegrast) (LLY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/obefazimod.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Obefazimod PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/obefazimod

```bibtex
@misc{secapidev_pdufa_obefazimod_20261116,
  title        = {Obefazimod PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/obefazimod}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_obefazimod_20261116","title":"Obefazimod PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/obefazimod","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
